LAI leadership Pharmathen has a leading focus on long acting injectable technologies (LAI), sustained release, and ophthalmic formulations with a broad, highly diversified portfolio and an extensive development pipeline. This creates opportunities to cross-sell advanced drug delivery platforms and lifecycle management services to customers seeking long-term treatment solutions and improved adherence.

Global footprint With manufacturing facilities approved by US FDA and EU, production capabilities serving 250 customers across more than 90 countries, Pharmathen presents scalable manufacturing and regulatory confirmation advantages for partners seeking international reach and accelerated market access.

Strategic growth Recent acquisitions and facility expansions, including the CBL Patras purchase and European expansion, indicate a growth trajectory and increased capacity. This suggests readiness to onboard new clients, support larger projects, and offer expanded turnkey services in Europe and beyond.

Collaborative potential Active co-development in psychiatry LAI with Neuraxpharm demonstrates openness to partnerships and joint development, signaling opportunities for BD teams to pursue similar co-development or licensing deals with Pharmathen’s LATT platforms and Life Cycle Management capabilities.

Innovation and sustainability Pharmathen emphasizes innovation through certified technological platforms and a strong emphasis on efficiency, patient adherence, and access to affordable medicines. This aligns with buyers seeking differentiated, compliant, and cost-effective delivery solutions, creating opportunities in price-constrained or payer-driven markets.